The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems

生物 癌细胞 癌症 细胞毒性 体内 细胞凋亡 癌症研究 Fas受体 细胞 计算生物学 药理学 体外 生物化学 程序性细胞死亡 生物技术 遗传学
作者
Henning Walczak,Peter H. Krammer
出处
期刊:Experimental Cell Research [Elsevier]
卷期号:256 (1): 58-66 被引量:621
标识
DOI:10.1006/excr.2000.4840
摘要

Peptide therapy has started since 1920s with the advent of insulin application, and now it has emerged as a new approach in treatment of diseases including cancer. Using anti-cancer peptides (ACPs) is a promising way of cancer therapy as ACPs are continuing to be approved and arrived at major pharmaceutical markets. Traditional cancer treatments face different problems like intensive adverse effects to patient's body, cell resistance to conventional chemical drugs and in some worse cases the occurrence of cell multidrug resistance (MDR) of cancerous tissues against chemotherapy. On the other hand, there are some benefits conceived for peptides usage in treatment of diseases specifically cancer, as these compounds present favorable characteristics such as smaller size, high activity, low immunogenicity, good biocompatibility in vivo, convenient and rapid way of synthesis, amenable to sequence modification and revision and there is no limitation for the type of cargo they carry. It is possible to achieve an optimum molecular and functional structure of peptides based on previous experience and bank of peptide motif data which may result in novel peptide design. Bioactive peptides are able to form pores in cell membrane and induce necrosis or apoptosis of abnormal cells. Moreover, recent researches have focused on the tumor recognizing peptide motifs with the ability to permeate to cancerous cells with the aim of cancer treatment at earlier stages. In this strategy the most important factors for addressing cancer are choosing peptides with easy accessibility to tumor cell without cytotoxicity effect towards normal cells. The peptides must also meet acceptable pharmacokinetic requirements. In this review, the characteristics of peptides and cancer cells are discussed. The various mechanisms of peptides' action proposed against cancer cells make the next part of discussion. It will be followed by giving information on peptides application, various methods of peptide designing along with introducing various databases. Future aspects of peptides for employing in area of cancer treatment come as conclusion at the end.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
瘦瘦沛柔发布了新的文献求助30
刚刚
1秒前
2秒前
5秒前
TanFT发布了新的文献求助10
5秒前
5秒前
6秒前
pluto应助chen采纳,获得10
7秒前
CodeCraft应助梅豪采纳,获得10
8秒前
不如一默发布了新的文献求助10
9秒前
陌君子筱发布了新的文献求助10
12秒前
14秒前
Blossom发布了新的文献求助10
14秒前
荧123456完成签到,获得积分20
14秒前
orixero应助keepa采纳,获得10
16秒前
16秒前
LSJ发布了新的文献求助10
17秒前
17秒前
17秒前
17秒前
18秒前
18秒前
郑石发布了新的文献求助10
19秒前
汉堡包应助yy采纳,获得10
20秒前
传奇3应助荧123456采纳,获得10
21秒前
在水一方应助科研通管家采纳,获得10
21秒前
顾矜应助科研通管家采纳,获得10
21秒前
小蘑菇应助科研通管家采纳,获得10
21秒前
汉堡包应助科研通管家采纳,获得10
21秒前
英俊的铭应助科研通管家采纳,获得10
22秒前
NexusExplorer应助科研通管家采纳,获得10
22秒前
深情安青应助科研通管家采纳,获得10
22秒前
CodeCraft应助科研通管家采纳,获得10
22秒前
打打应助科研通管家采纳,获得10
22秒前
香蕉觅云应助科研通管家采纳,获得10
22秒前
22秒前
CipherSage应助科研通管家采纳,获得10
22秒前
水三寿发布了新的文献求助10
22秒前
慕青应助科研通管家采纳,获得30
22秒前
我是老大应助科研通管家采纳,获得10
22秒前
高分求助中
Impact of Mitophagy-Related Genes on the Diagnosis and Development of Esophageal Squamous Cell Carcinoma via Single-Cell RNA-seq Analysis and Machine Learning Algorithms 2000
How to Create Beauty: De Lairesse on the Theory and Practice of Making Art 1000
Gerard de Lairesse : an artist between stage and studio 670
大平正芳: 「戦後保守」とは何か 550
Contributo alla conoscenza del bifenile e dei suoi derivati. Nota XV. Passaggio dal sistema bifenilico a quello fluorenico 500
Multiscale Thermo-Hydro-Mechanics of Frozen Soil: Numerical Frameworks and Constitutive Models 500
T/CAB 0344-2024 重组人源化胶原蛋白内毒素去除方法 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 2997401
求助须知:如何正确求助?哪些是违规求助? 2657886
关于积分的说明 7194651
捐赠科研通 2293291
什么是DOI,文献DOI怎么找? 1215887
科研通“疑难数据库(出版商)”最低求助积分说明 593350
版权声明 592825